Business Description
Inventiva SA
ISIN : FR0013233012
Total Employee Number:
77Compare
Compare
Traded in other countries / regions
IVA.FranceIVA.USA0RNK.UK6IV.Germany IPO Date
2020-10-17Description
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.86 | |||||
Equity-to-Asset | -0.11 | |||||
Debt-to-Equity | -2.1 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.84 | |||||
Beneish M-Score | -4.5 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -56.6 | |||||
3-Year EBITDA Growth Rate | -10.7 | |||||
3-Year EPS without NRI Growth Rate | 6.3 | |||||
3-Year FCF Growth Rate | 19.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 30.27 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 230.79 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 20.53 | |||||
9-Day RSI | 17.14 | |||||
14-Day RSI | 19.54 | |||||
3-1 Month Momentum % | -14.31 | |||||
6-1 Month Momentum % | 17.12 | |||||
12-1 Month Momentum % | 83.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.16 | |||||
Quick Ratio | 3.16 | |||||
Cash Ratio | 2.98 | |||||
Days Sales Outstanding | 361.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -66.1 | |||||
Shareholder Yield % | -29.17 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2964.15 | |||||
Net Margin % | -7899.58 | |||||
EBITDA Margin % | -7055.79 | |||||
FCF Margin % | -2345.1 | |||||
OCF Margin % | -2339.59 | |||||
ROA % | -194.07 | |||||
ROIC % | -285 | |||||
3-Year ROIIC % | -331.42 | |||||
ROC (Joel Greenblatt) % | -8033.14 | |||||
ROCE % | -330.62 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 74.88 | |||||
EV-to-EBIT | -1.73 | |||||
EV-to-EBITDA | -1.75 | |||||
EV-to-Revenue | 123.62 | |||||
EV-to-Forward-Revenue | 63.98 | |||||
EV-to-FCF | -5.27 | |||||
Price-to-GF-Value | 12.75 | |||||
Earnings Yield (Greenblatt) % | -57.8 | |||||
FCF Yield % | -14.5 |
Inventiva SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inventiva SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 145 days | ||
| Second quarter earnings results for 2026 | 2026-09-25 | In 89 days | ||
| General meeting for 2025 | 2026-06-30 14:00 | In 3 days | ||
| Portzamparc BNP Paribas group mid & small caps conference | 2026-06-25 | 3.06 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 17:30 | 4.55 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-26 | 4.55 (+0.00%) | ||
| Annual report for 2025 | 2026-04-08 | 4.75 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-31 08:00 | 4.76 (+0.95%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 5.03 (-0.30%) | ||
| Guidance call for 2026 | 2026-02-11 13:00 | 4.98 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in TradeUP Acquisition Corp, Inventiva ADR, Relmada Therapeutics, P3 Health Partners, or Nikola Corp? | 2023-09-21 |
Articles on Inventiva SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers